Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2011-07-05
2011-07-05
Nashed, Nashaat (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S001500
Reexamination Certificate
active
07973005
ABSTRACT:
The present invention relates to methods for the treatment of exacerbation periods of pulmonary diseases, particularly chronic obstructive pulmonary diseases, by administering alpha-1 antitrypsin (AAT) to a subject in need thereof. Particularly, the present invention discloses the efficient treatment of exacerbation periods of pulmonary diseases by administering AAT via inhalation.
REFERENCES:
patent: 5093316 (1992-03-01), Lezdey et al.
patent: 5518179 (1996-05-01), Humberstone et al.
patent: 5618786 (1997-04-01), Roosdorp et al.
patent: 5780440 (1998-07-01), Lezdey et al.
patent: 6462180 (2002-10-01), Lebing et al.
patent: 6655379 (2003-12-01), Clark et al.
patent: 2008/0060640 (2008-03-01), Waldner et al.
patent: 199 53 317 (2001-02-01), None
patent: WO 01/34232 (2001-05-01), None
patent: WO 03/026832 (2003-04-01), None
patent: WO 2004/014569 (2004-02-01), None
patent: WO 2004/052436 (2004-06-01), None
patent: WO 2005/027821 (2005-03-01), None
patent: WO 2005/048985 (2005-06-01), None
patent: WO 2005/086915 (2005-09-01), None
International Search Report PCT/IL2007/000181 Dated Sep. 21, 2007.
R. Hubbard et al.,Anti-Neutrophil-Elastase Defenses Of The Lower Respiratory Tract In a 1-Antitrypsin Deficiency Directly Augmented With An Aerosol of a 1-Antitrypsin, Aug. 1, 1989, pp. 206-212, Annals of Internal Medicine, vol. 3, No. 3.
P. Brand et al.,Alveolar Deposition Of Monodisperse Aerosol Particles In The Lung Of Patients With Chronic Obstructive Pulmonary Disease, Jan./Aug. 2002, Abstract, Experimental Lung Research, vol. 28, No. 1.
P. Brand et al.,Peripheral Deposition Of Alpha1-Protease Inhibitor Using Commercial Inhalation Devices, Aug. 2003, Abstract, European Respiratory Journal, vol. 22, No. 2.
G. Hansen et al.,Alpha-1-Proteinase Inhibitor Abrogates Proteolytic And Secretagogue Activity Of Cystic Fibrosis Spectrum, 1995, Abstract, Respiration, vol. 62, No. 3.
International Search Report, application No. PCT/IL2007/000182, dated Oct. 5, 2007.
K. Kawabata et al. “Delayed Neutrophil Elastase Inhibition Prevents Subsequent Progression of Acute Lung Injury Induced by Endotoxin Inhalation in Hamsters”, American Journal of Respiratory And Critical Care Medicine, vol. 161, pp. 2013-2018 (2000).
S. Yasui et al., “A Specific Neutrophil Elastase Inhibitor (ONO-5046-Na) Attenuates LPS-Induced Acute Lung Inflammation In The Hamster”, European Respiratory Journal , vol. 8, pp. 1293-1299 (1995).
Z. Jie et al., “Protective Effects Of α1-Antitrypsin On Acute Lung Injury In Rabbits Induced By Endotoxin”, Chinese Medical Journal (English), vol. 116(11), pp. 1678-1682 (2003).
Kamada Ltd.
Nashed Nashaat
Winston & Strawn LLP
LandOfFree
Alpha-1 antitrypsin for treating exacerbation episodes of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-1 antitrypsin for treating exacerbation episodes of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-1 antitrypsin for treating exacerbation episodes of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675886